Chat
Drug Profile, Targeted with Interpretation by Tandem Mass Spectrometry and Enzyme Immunoassay, Urine
Copy Utility
Ordering Recommendation
Qualitative test to monitor medication compliance and to detect undisclosed drug/substance use in support of pain management, substance use disorders treatment, and other pharmacotherapies involving controlled substances. Expert result interpretation is provided by a faculty clinical toxicologist.
Submission of a medication history is required to optimize reporting; refer to ARUP's Medication Submission Guidelines for details. If a medication history is not available or interpretation is not desired, refer to Drug Profile, Targeted by Tandem Mass Spectrometry and Enzyme Immunoassay, Urine (2007479).
This test does not distinguish between the delta-8 and delta-9 forms of THC or their metabolites.
Mnemonic
Methodology
Quantitative Liquid Chromatography-Tandem Mass Spectrometry/Qualitative Enzyme Multiplied Immunoassay Technique (EMIT)/Quantitative Spectrophotometry
Performed
Sun-Sat
Reported
1-4 days
New York DOH Approval Status
Specimen Required
Information on the patient's current medications must be submitted with the order. Include trade name, generic name, dosing frequency and date of last dose, if known. Alternatively, please indicate if no prescription medication or drugs are being taken.
Random urine.
Transfer 4 mL each into two (2) ARUP Standard Transport Tubes urine with no additives or preservatives. (Min: 2 mL each)
Refrigerated
Specimens exposed to repeated freeze/thaw cycles.
Ambient: 1 week (Clonazepam may be unstable at ambient condition beyond three days); Refrigerated: 1 month; Frozen: 1 month
Reference Interval
| Drugs covered and range of cutoff concentrations. Note: Some drugs are identified based on the presence of unique drug metabolites not listed below. |
|
|---|---|
| Drugs/Drug Classes |
Range of Cutoff Concentrations |
| Barbiturates | 200 ng/mL |
| Benzodiazepine-like: alprazolam, clonazepam, diazepam, lorazepam, midazolam, nordiazepam, oxazepam, temazepam, zolpidem |
20 - 60 ng/mL |
| Cannabinoids (11-nor-9-carboxy-THC) | 50 ng/mL |
| Ethyl Glucuronide | 500 ng/mL |
| Muscle Relaxant(s): carisoprodol, meprobamate |
100 ng/mL |
| Opiates/Opioids: buprenorphine, codeine, fentanyl, heroin, hydrocodone, hydromorphone, meperidine, methadone, morphine, naloxone, oxycodone, oxymorphone, tapentadol, tramadol |
2-200 ng/mL |
| GABA analogues: Gabapentin, pregabalin |
3,000 ng/mL |
| Phencyclidine (PCP) | 25 ng/mL |
| Stimulants: amphetamine, cocaine, methamphetamine, methylphenidate, MDMA (Ecstasy), MDEA (Eve), MDA, phentermine |
50-200 ng/mL |
Interpretive Data
Methodology: Qualitative Enzyme Immunoassay and Qualitative Liquid Chromatography-Tandem Mass Spectrometry, Quantitative Spectrophotometry
The absence of expected drug(s) and/or drug metabolite(s) may indicate non-compliance, inappropriate timing of specimen collection relative to drug administration, poor drug absorption, diluted/adulterated urine, or limitations of testing. The concentration must be greater than or equal to the cutoff concentration to be reported as present. If specific drug concentrations are required, contact the laboratory within two weeks of specimen collection to request confirmation and quantification by a second analytical technique. Interpretive questions should be directed to the laboratory.
Results based on immunoassay detection that do not match clinical expectations should be interpreted with caution. Confirmatory testing by mass spectrometry for immunoassay-based results is available if ordered within two weeks of specimen collection. Additional charges apply.
For medical purposes only; not valid for forensic use.
This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.
Laboratory Developed Test (LDT)
Note
Creatinine concentration is also provided. The carisoprodol immunoassay has cross-reactivity to carisoprodol and meprobamate.
Hotline History
Hotline History
CPT Codes
80326; 80347; 80364; 80355; 80307 (Alt code: G0481)
Components
| Component Test Code* | Component Chart Name | LOINC |
|---|---|---|
| 0090386 | Creatinine, Urine | 2161-8 |
| 2007636 | Codeine (cutoff 40 ng/mL) | 3507-1 |
| 2007637 | Morphine (cutoff 20 ng/mL) | 3830-7 |
| 2007638 | 6-acetylmorphine (cutoff 20 ng/mL) | 10976-9 |
| 2007640 | Oxycodone (cutoff 40 ng/mL) | 10998-3 |
| 2007641 | Noroxycodone (cutoff 100 ng/mL) | 61424-8 |
| 2007642 | Oxymorphone (cutoff 40 ng/mL) | 11247-4 |
| 2007643 | Noroxymorphone (cutoff 100 ng/mL) | 89302-4 |
| 2007644 | Hydrocodone (cutoff 40 ng/mL) | 12308-3 |
| 2007646 | Norhydrocodone (cutoff 100 ng/mL) | 61421-4 |
| 2007647 | Hydromorphone (cutoff 20 ng/mL) | 9834-3 |
| 2007649 | Buprenorphine (cutoff 5 ng/mL) | 3414-0 |
| 2007651 | Norbuprenorphine (cutoff 20 ng/mL) | 58362-5 |
| 2007652 | Fentanyl (cutoff 2 ng/mL) | 11235-9 |
| 2007653 | Norfentanyl (cutoff 2 ng/mL) | 43199-9 |
| 2007654 | Meperidine metabolite (cutoff 50 ng/mL) | 58388-0 |
| 2007655 | Tapentadol (cutoff 100 ng/mL) | 72485-6 |
| 2007656 | Tapentadol-o-Sulf (cutoff 200 ng/mL) | 72485-6 |
| 2007658 | Methadone (cutoff 150 ng/mL) | 3773-9 |
| 2007660 | Tramadol (cutoff 100 ng/mL) | 43219-5 |
| 2007662 | Amphetamine (cutoff 50 ng/mL) | 19343-3 |
| 2007663 | Methamphetamine (cutoff 200 ng/mL) | 3779-6 |
| 2007664 | MDMA- Ecstasy (cutoff 200 ng/mL) | 14267-9 |
| 2007665 | MDA (cutoff 200 ng/mL) | 42253-5 |
| 2007666 | MDEA- Eve (cutoff 200 ng/mL) | 61048-5 |
| 2007668 | Phentermine (cutoff 100 ng/mL) | 3957-8 |
| 2007670 | Benzoylecgonine (cutoff 150 ng/mL) | 3393-6 |
| 2007672 | Alprazolam (cutoff 40 ng/mL) | 9351-8 |
| 2007673 | Alpha-OH-Alprazolam (cutoff 20 ng/mL) | 61036-0 |
| 2007674 | Clonazepam (cutoff 20 ng/mL) | 19245-0 |
| 2007675 | 7-Aminoclonazepam (cutoff 40 ng/mL) | 61030-3 |
| 2007676 | Diazepam (cutoff 50 ng/mL) | 3550-1 |
| 2007677 | Nordiazepam (cutoff 50 ng/mL) | 3861-2 |
| 2007678 | Oxazepam (cutoff 50 ng/mL) | 12361-2 |
| 2007679 | Temazepam (cutoff 50 ng/mL) | 61060-0 |
| 2007680 | Lorazepam (cutoff 60 ng/mL) | 18187-5 |
| 2007681 | Midazolam (cutoff 20 ng/mL) | 19585-9 |
| 2007682 | Zolpidem (cutoff 20 ng/mL) | 33338-5 |
| 2007684 | Barbiturates (cutoff 200 ng/mL) | 3377-9 |
| 2007687 | Ethyl Glucuronide (cutoff 500 ng/mL) | 55349-5 |
| 2007688 | Marijuana Metabolite | 3435-5 |
| 2007689 | PCP (cutoff 25 ng/mL) | 3936-2 |
| 2007690 | Carisoprodol (cut-off 100 ng/mL) | 21142-5 |
| 2007691 | Targeted drug profile panel | 8251-1 |
| 2009289 | EER Tgt drug prof, MS/EMIT, UR, Interp | 11526-1 |
| 2009290 | DRUGS EXPECTED | 48767-8 |
| 2009291 | Targeted drug profile Interp | 48767-8 |
| 2013281 | Methylphenidate (cutoff 100 ng/mL) | 3808-3 |
| 3003499 | Alpha-OH-Midazolam (cutoff 20 ng/mL) | 94108-8 |
| 3003500 | Zolpidem Metabolite (cutoff 100 ng/mL) | 94103-9 |
| 3003501 | Gabapentin (cutoff 3,000 ng/mL) | 92648-5 |
| 3003502 | Naloxone (cutoff 100 ng/mL) | 92649-3 |
| 3003503 | Pregabalin (cutoff 3,000 ng/mL) | 92651-9 |
Aliases
- abstinence verification
- addiction management
- Comprehensive hybrid
- high res
- high-res
- hybrid
- medication adherence
- medication compliance
- Pain management, (drug screen, targeted, urine)
- prenatal drug screen
- substance use disorder
Feedback
